Fabry disease and Drug Development

Fabry disease is rare inherited enzyme deficiency disease and it is named after its discoverer  Johannes Fabry.  A deficiency of the enzyme alpha galactosidase A due to mutation causes a glycolipid known as globotriaosylceramide (abbreviated as Gb3, GL-3, or ceramide trihexoside) to accumulate within the blood vessels, other tissues, and organs. This accumulation leads to an impairment of their proper function. (Wikipedia)

There are two enzyme replacement therapies are currently available for treating Fabry disease, which are Agalsidase alpha (Replagal from Shire) and Agalsidase beta (Fabrazyme from Genzyme).

Recently, patient groups petitioned open licence Genzyme’s patents covering Fabrazyme due to ongoing shortage of drug supply. Another drug shire’s Replagal is not approved in USA.

GSK now licensed new drug for Fabry disease, which is migalastat HCl.

Image of Chemical Structure

Migalastat is first oral therapy for treating Fabry disease and pharmacologically this is alpha 2 galactosidase stimulant. Co-administration of Migalastat with Enzyme replacement therapy is being studied. Amicus Therapeutics would receive upfront payment of $30 million. In addition to the upfront payment, Amicus is eligible to receive about $170 million upon the successful achievement of development and commercialization milestones, as well as tiered double-digit royalties on global sales.

About Guna

Interested to learn things around me
This entry was posted in Uncategorized. Bookmark the permalink.

2 Responses to Fabry disease and Drug Development

  1. Pingback: Amicus Study 011 In Fabry Disease Released Today ( $FOLD) « Translating Healthcare

  2. Pingback: Amicus Study 011 In Fabry Disease Released Today ( $FOLD) | Translating Healthcare

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s